Haemonetics and CSL Plasma Announce a Long-Term Plasma Collection Software Agreement

News provided by

Mar 05, 2015, 08:00 ET

BRAINTREE, Mass. and BOCA RATON, Fla., March 5, 2015 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) and CSL Plasma, Inc. announced today that CSL Plasma, Inc. has selected Haemonetics' Next Generation Donor Management System ("NextGen DMS"), an innovative software application for the management of plasma collection, as its future system for managing more than 100 plasma donation centers across the U.S. and Europe. The two companies completed a significant long-term technology agreement for a fully integrated software system designed to enable greater efficiency and to advance the collection operations performance.

Haemonetics had previously announced that it had completed a long-term contract with an un-named customer for the customization of its new plasma donor management software during fiscal 2016, for use in the customer's collection facilities in the future. Today's announcement identified CSL Plasma, Inc. as that customer.

"At CSL Plasma, our success is achieved through innovation and we recognize the power of technology to seamlessly integrate and streamline all aspects of our plasma collection activities and equipment," explained Randy Furby, General Manager of CSL Plasma. "We are excited to extend our innovation strategy by partnering with Haemonetics to rollout their NextGen DMS software across our collection network to bring us to the next level of a truly integrated solution."

"We are excited that CSL Plasma shares our vision and we are confident that the combination of our leading strengths will be welcomed by the plasma industry," commented Pete Allen, President of Global Plasma for Haemonetics. "This strategic global partnership will help us expand the capabilities of our advanced solutions for the industry, which includes an enhancement to our current plasma collection device that will support two-way data communication, and will complement our new software offering."

Haemonetics and CSL Plasma share the vision that Haemonetics' software and device integration is the next key phase to improving plasma collection operational efficiency. Haemonetics will continue to work closely with the entire plasma collection industry to meet its current and future needs, remaining focused on innovative offerings and global partnerships.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit the web site www.haemonetics.com.

ABOUT CSL PLASMA

CSL Plasma, Inc. operates as a collector of human blood plasma for use in manufacturing life-saving biotherapies and is one of the world's largest collectors of human plasma. CSL Plasma, Inc. has plasma collection centers in the U. S. and Germany, state-of-the-art testing laboratories that features some of the most advanced technology, instrumentation and automation in the field; three logistics centers and corporate headquarters in Boca Raton, Florida.

CSL Plasma, Inc. operates as a subsidiary of CSL Behring LLC, headquartered in King of Prussia, Pennsylvania. CSL Behring is a member of the CSL Group of companies. Its parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. To learn more about CSL Plasma, visit the web site www.cslplasma.com.

CONTACT:
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
[email protected]
Alt. (781) 356-9613

Logo - http://photos.prnewswire.com/prnh/20150128/172006LOGO

SOURCE Haemonetics Corporation